COMP <GO>
AGIO vs HRMY // EV/EBITDA & P/E VALUATION
Agios Pharmaceuticals Inc. (NASDAQ) VS. Harmony Biosciences Holdings Inc. (NASDAQ) • 15-METRIC TALLY: AGIO 3
— HRMY 7
■ METRIC PARITY
LAST: $37.23 (-2.33%) • MKT CAP: $2.22B
valuation
—
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
valuation
7.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGIO VS. HRMY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGIO | HRMY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.30% | 77.20% | +11.10 | AGIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -33.80% | 63.00% | -96.80 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 7.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.97% | 15.48% | -32.45 | HRMY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.00% | -84.00 | HRMY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 18.30% | -78.30 | HRMY | /net-margins <GO> |
| Revenue Growth (YoY) | 48.00% | 21.50% | +26.50 | AGIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.84 | 5.38 | +6.46 | AGIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.2 | 51.1 | -13.83 | HRMY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 11.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.22B | $2.25B | -$24.6M | HRMY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGIO REV | HRMY REV | AGIO GROSS % | HRMY GROSS % | AGIO FCF | HRMY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $54.0M | $868.5M | 88.3% | 77.2% | -$377.3M | $347.9M |
| FY 2024 | $36.5M | $714.7M | 88.6% | 78.1% | -$391.5M | $218.7M |
| FY 2023 | $26.8M | $582.0M | — | — | -$296.1M | $219.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGIO // BETA —
HRMY // BETA —